ReviewJournal of leukocyte biology2013

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Andrew M Intlekofer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.